SiDMAP’s new Japanese clients will use SiDMAP’s services to study the mechanisms of action and identify potential efficacy biomarkers for drugs designed to treat diseases such as diabetes, obesity and neurological disorders.
Using SiDMAP’s services, drug researchers can identify specific metabolic evidence, or biomarkers, of drug efficacy or toxicity that can be detected and measured reliably and reproducibly, in vitro or in vivo.
William Robbins, COO of SiDMAP, said: “We are eager to expand our business in Japan. Our metabolomics testing and biomarker development services are clearly gaining wider acceptance, as evidenced not only by our geographic expansion, but also by the wider range of drug classes that clients wish to test using our stable isotope tracer technology.”